937039-45-7
Chemical Structure
Pimelic Diphenylamide 106
Synonym(s): RGFA-8; TC-H 106; Histone Deacetylase Inhibitor VII
- CAS No.: 937039-45-7
- Formula:C20H25N3O2
- Molecular Weight:339.43
IUPAC Name: N1-(2-aminophenyl)-N7-(p-tolyl)heptanediamide
InChIKey: WTKBRPXPNAKVEQ-UHFFFAOYSA-N
SMILES: O=C(NC1=CC=CC=C1N)CCCCCC(NC2=CC=C(C)C=C2)=O
Biological Activity: Pimelic Diphenylamide 106 (TC-H 106) is a slow, tight binding class I HDAC inhibitor (inhibits HDAC1, 2, and 3 with IC50 values of 150 nM, 760 nM, and 370 nM, respectively), with no activity against class II HDACs. Pimelic Diphenylamide 106 modulates dopamine concentration and protects dopamine cells by inducing VMAT2 expression. Pimelic Diphenylamide 106 can be used in the study of neuropsychiatric diseases such as attention deficit hyperactivity disorder (ADHD)[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Pimelic Diphenylamide 106 | 98.54% | Pimelic Diphenylamide 106 (TC-H 106) is a slow, tight binding class I HDAC inhibitor (inhibits HDAC1, 2, and 3 with IC50 values of 150 nM, 760 nM, and 370 nM, respectively), with no activity against class II HDACs. Pimelic Diphenylamide 106 modulates dopamine concentration and protects dopamine cells by inducing VMAT2 expression. Pimelic Diphenylamide 106 can be used in the study of neuropsychiatric diseases such as attention deficit hyperactivity disorder (ADHD). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Chou CJ, et al. Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases. J Biol Chem. 2008 Dec 19;283(51):35402-35409. [Content Brief]
- [2]. Xu C, et al. Chemical probes identify a role for histone deacetylase 3 in Friedreich's ataxia gene silencing. Chem Biol. 2009 Sep 25;16(9):980-989. [Content Brief]
- [3]. Lee, et al. "Dopaminergic cell protection and alleviation of neuropsychiatric disease symptoms by VMAT2 expression through the class I HDAC inhibitor TC‐H 106." Pharmacology Research & Perspectives 11.5 (2023): e01135. [Content Brief]
Keywords
